NEWS PROVIDED BY – Occlutech – 05 Apr, 2017, 07:00 ET SCHAFFHAUSEN, Switzerland, April 5, 2017 /PRNewswire/ — Occlutech, a leading innovator of implants to treat structural heart disease, today announced that it has obtained European CE Mark approval for its Perimembranous Ventricular Septal Defect (PmVSD) Occluder. The device is a […]